GeNeuro SA (GNROp)

Overview

GeNeuro SA is a clinical-stage biopharmaceutical company based in Plan-les-Ouates, Switzerland, focused on the development of innovative treatments for neurodegenerative and autoimmune diseases. Since its incorporation in 2006, the company has leveraged its expertise in therapeutic antibodies to address complex medical conditions. GeNeuro's strategic collaborations with leading research institutes and academic centers are instrumental in its mission to advance novel treatments for challenging neurological disorders and long-haul COVID patients. These partnerships underline the company's commitment to exploring the therapeutic potential of targeting endogenous retroviruses to ameliorate disease symptoms and potentially alter the course of neurological and autoimmune diseases.

Products and Services

GeNeuro SA is dedicated to developing a pipeline of therapeutic candidates aimed at treating a variety of challenging diseases:

• Temelimab: This monoclonal antibody is at the forefront of GeNeuro's development efforts. Temelimab is designed to neutralize a pathogenic protein from the HERV-W family, offering a novel approach to treat neurodegenerative and autoimmune diseases. It is currently being investigated for its potential in:
  • Type 1 Diabetes: Aiming to address the autoimmune aspect of diabetes by mitigating the underlying inflammatory processes.
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Targeting the inflammatory responses in the nervous system that contribute to this autoimmune disorder.
• GNK301: Another key asset in GeNeuro's portfolio, GNK301, is under development as part of the company's broader strategy to tackle diseases associated with the HERV-W family. The specific indications and therapeutic targets for GNK301 are part of ongoing research efforts and reflect GeNeuro’s commitment to expanding the range of diseases addressed by its products.

In addition to these product development efforts, GeNeuro has forged significant research collaboration agreements that enable the exploration and validation of its therapeutic approaches. These include collaborations with The National Institute of Neurological Disorders and Stroke for developing therapies against amyotrophic lateral sclerosis (ALS), and with various academic centers to understand and treat inflammatory psychosis. Furthermore, partnerships with the International Center for Infectiology Research and Northwestern University are instrumental in advancing the study of HERV-W ENV proteins in patients suffering from long-haul COVID, highlighting the potential broad applicability of GeNeuro’s technology in addressing post-viral syndromes and related conditions.